Mutations in the breast cancer susceptibility gene 1 (BRCA1) account for a substantial percentage of familial breast and ovarian cancers. Although BRCA1 is thought to function within the nucleus, it has also been located in the cytoplasm. In addition, BRCA1 accumulates in the nucleus of cells treated with leptomycin B, an inhibitor of chromosome region maintenance 1-mediated nuclear export, indicative of its active nuclear export via this pathway. The nuclear export signal in BRCA1 has been described as consisting of amino acid residues 81-99. However, a number of other tumor suppressors have multiple nuclear export sequences, and we sought to determine whether BRCA1 did also. Here, we report that BRCA1 contains a second nuclear export sequence that comprises amino acid residues 22-30. By use of the human immunodeficiency virus-1 Rev complementation assay, this sequence was shown to confer export capability to an export-defective Rev fusion protein. The level of export activity was comparable with that of residues 81-99 comprising the previously reported nuclear export sequence in BRCA1. Mutation of leucine 28 to an alanine reduced nuclear export by ϳ75%. In MCF-7 cells stably transfected with a BRCA1 cDNA containing mutations in this novel sequence or the previously reported export sequence, BRCA1 accumulated in the nucleus. These data imply that BRCA1 contains at least two leucine-dependent nuclear export sequences.
Germ line mutations in the two known breast cancer susceptibility genes, BRCA1 and BRCA2, contribute to the development of a large percentage of hereditary breast cancers. Approximately 20% of families with an inherited susceptibility to breast cancer have a mutation in BRCA1 (1), whereas about 90% of the families with an increased prevalence of both breast and ovarian cancers have mutations within this gene (2) . In contrast, mutations in BRCA1 do not appear to contribute significantly to the development of nonfamilial cancers. Rather, there is a reduced level of BRCA1 expression in sporadic breast cancer (3) .
The primary structure of BRCA1 contains several features that support a nuclear function for the protein. First, BRCA1 has two carboxyl-terminal domains, sequences present in several cell cycle checkpoint proteins, such as p53-binding protein 1 (4) , DNA repair protein XRCC (5) , and the retinoblastoma family of proteins (6) . This structural feature, combined with the reported binding of BRCA1 to Rad 50 (7) and/or Rad 51 (8) as well as its ability to facilitate transcription-coupled DNA repair (9) , implicates BRCA1 in the cellular response pathway for repair of DNA damage. Second, BRCA1 has an acidic carboxyl terminus that acts as a transactivation domain (10) and supports the role of BRCA1 as a transcriptional co-activator. Third, BRCA1 also has two nuclear localization sequences (11, 12) , suggestive of a nuclear localization and function for the protein.
Like several other tumor suppressors, including adenomatous polyposis coli (13, 14) , p53 (15, 16) and Ini (integrase interactor 1)/hSNF5 (17) , BRCA1 undergoes active nuclear export. The dual nuclear-cytoplasmic localization suggests that shuttling of these proteins may be important for their functions. The most common mechanism for nuclear export of proteins is through the chromosome region maintenance (CRM1) 1 pathway (18) . Proteins that utilize this pathway for nuclear export contain a characteristic pattern of hydrophobic amino acids that interact with the CRM1/exportin 1 receptor. This interaction is stabilized through an association with RanGTP, resulting in the translocation of the cargo protein from the nucleus into the cytoplasm.
The presence of a functional nuclear export sequence (NES) in BRCA1 was first reported by Rodriguez and Henderson (19) , who localized the NES to amino acid residues 81-99. Here, we provide evidence that a second sequence in BRCA1, amino acid residues 22-30, can mediate nuclear export. Mutation of this sequence resulted in nuclear sequestration of the protein, similar to the results obtained when the sequence corresponding to amino acids 81-99 was mutated. These studies suggest that there are two nuclear export sequences within BRCA1.
EXPERIMENTAL PROCEDURES
Plasmid Constructs-The Rev⌬3NI-abl NES wild-type and Rev⌬3NI-abl NES mutant plasmids (provided by Thomas Hope, Salk Institute) have been described previously (21) . Complementary oligonucleotides corresponding to the coding sequence for amino acids 22-30, 81-99, and 591-600 of BRCA1 were synthesized (Ransom Hill Bioscience) with BglII and XbaI ends, annealed, and subcloned into the respective sites of the Rev⌬NI-abl NES mutant. The same strategy was used when leucines 28 and 30 were mutated to alanines. All cloning and mutations * This work was supported by the National Institutes of Health-NCRR-supported Research Centers in Minority Institutions Grant 2G12RR03032 (to M. E. T.), NCI, National Institutes of Health Grant K01 CA89494 (to M. E. T.), and National Institutes of Health Grant R01 CA85269 (to J. T. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: To generate the pEGFPC1BRCA1 construct, the multiple cloning sequence of pEGFPC1 (Clontech) was excised with BspEI and BamHI. Complementary oligonucleotides (CCGGAACCCGGGAAGCTTGCGG-CCGCCTCGAGG and GATCCCTCGAGGCGGCCGCAAGCTTCCCGG-GTT) were annealed and ligated to the digested pEGFPC1 to create a new multiple cloning sequence. The new plasmid was then digested with NotI and XhoI, and the cDNA for BRCA1 was cloned into these sites. The L28A and C27G mutations were generated by PCR using BRCA1 cloned into pCRScript (Stratagene) as the template. The forward primers were GTTCCTTGATCAACTCAGCACAGATGGGA (L28A) and GTTCCTTGATCAACTCCAGTCCGATGGGA (C27G), and the reverse primer for each was ATAGCGGCCGCATGGATTATCT-GCT. PCR parameters were 94°C for 45 s, 42°C for 45 s, and 72°C for 1 min for 30 cycles followed by a final 10-min incubation at 72°C. The PCR product was cloned into the NotI and BclI sites of pCRScript-BRCA1. The cDNA was then excised and ligated into the NotI and XhoI sites of the modified pEGFPC1 plasmid. The m2 mutations (F93A and L95A) (19) within the NES at amino acids 81-99 of BRCA1 were generated using the QuikChange XL site-directed mutagenesis kit (Stratagene) and were made directly in the pEGFPC1BRCA1 construct. The primers were GAAAATCATTTGTGCTGCTCAGGCTGACACAGG-TTTGGAGTATG and CATACTCCAAACCTGTGTCAGCCTGAGCAGC-ACAAATGATTTTC.
HIV-1 Rev Complementation Assay-HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FetalClone III (HyClone) and grown at 37°C in 5% CO 2. Cells were transfected using either a calcium phosphate coprecipitation method (20) or GeneJammer (Stratagene). A total of 2 g of DNA was transfected as described previously (21) using the pCMV128 chloramphenicol acetyltransferase (CAT) plasmid (a gift from Thomas Hope, Salk Institute). ␤-Galactosidase was assayed as described previously (22), and CAT assays were performed as described previously (22) or with the FAST CAT chloramphenicol acetyltransferase assay kit (Molecular Probes). Statistical analyses were performed and graphs generated with the GraphPad Prism software.
Stable Transfectants and Immunofluorescence-MCF-7 cells were transfected with 16 g of each cDNA using DMRIE-C (Invitrogen). Forty-eight h after transfection, 500 g/ml G418 was added. Individual clones were selected and expanded in the continued presence of G418.
Transfected cells were plated onto 22-mm coverslips overnight prior to fixation in 2% paraformaldehyde at 4°C for 30 min. Cells were washed twice in 0.1 M glycine/Tris, pH 7.4, and then once with phosphate-buffered saline. Cells were blocked in phosphate-buffered saline with 5% donkey serum, 1% bovine serum albumin, and 0.1% Triton X-100. A polyclonal anti-GFP antibody (Affinity Bioreagents) was used at 1:200 in the blocking solution. Secondary antibody was fluorescein isothiocyanate-donkey anti-rabbit IgG (Jackson Immunoresearch) diluted 1:100 in blocking solution. Nuclei were detected with propidium iodide, and coverslips were mounted on slides with Vectashield (Vector Laboratories). Cells were visualized with a Zeiss Axiophot fluorescence microscope, and photographs were prepared with the Adobe Photoshop software.
RESULTS
Prediction of a Novel BRCA1 NES-It has been demonstrated that BRCA1 undergoes active nuclear export via the CRM1 pathway and that this export is mediated by a Rev-like NES located between amino acids 81 and 99 (19) . Because the presence of multiple export sequences has been shown for a number of tumor suppressors, we searched for additional putative export sequences within BRCA1 using the newly developed NES prediction server, NetNES (23) . Analysis of the human BRCA1 sequence (NCBI accession number P38398) by NetNES revealed only one residue, leucine 95, with a NES motif score Ͼ 0.5 (Table I ). This residue is within the previously reported BRCA1 NES located at amino acid residues 81-99 (19) . We found three additional residues, leucines 30, 598, and 791, that had scores of 0.354, 0.324, and 0.363, respectively. Inspection of the sequence surrounding these residues suggested that none of them fit the consensus sequence for a NES exactly (Table II) , similar to the observation by la Cour et al. (23) that a number of NES deviate from the consensus sequence. We then compared these sequences with the NES of other proteins by aligning them based on the core region (LXL) and upstream critical hydrophobic residues (Table II) . This alignment suggested that the variable spacing defined by the consensus sequence could result in a NES consisting of 8 -19 residues (24, 25) . The minimal sequences surrounding leucines 30, 598, and 791 that could comprise a NES were 9, 10, and 11 residues, respectively. Moreover, two of the residues, leucines 30 and 598, had hidden Markov model scores (23) , one of the models used to assign a NES score, that exceeded the others by 5-10-fold. Based on these observations, we used the HIV-1 Rev complementation assay to determine whether the sequence surrounding leucines 30 and 598 could comprise a functional NES.
BRCA1 Serve as a Leucine-dependent NES-To determine whether residues 22-30 or 591-600 in BRCA1 were capable of mediating nuclear export, the HIV-1 Rev complementation assay was used (26) . This technique measures the ability of a putative NES, fused to an exportdefective Rev protein, to mediate the nuclear export of Rev. Rev can escort any intron-containing mRNA from the nucleus to the cytoplasm, and translation can occur. In our studies, we used an intron-disrupted CAT gene as the reporter. Thus, the acetylation resulting from the activity of CAT would be a measure of 
Nuclear Export Sequence in BRCA1
the nuclear export of the CAT mRNA, which, in turn, is dependent on the nuclear export of Rev. The results show that the sequence encoding amino acids 22-30 resulted in an approximate 10-fold increase in acetylation over that occurring in cells transfected with the CAT vector, CMV128, alone (Fig. 1A) . This increase was similar to that observed with the positive control, the c-abl NES. The sequence between amino acids 591 and 600 of BRCA1 showed a consistent but insignificant increase in acetylation. It has been demonstrated that mutation of the first leucine within the core motif of the NES abrogates export activity, whereas mutation of the second leucine within this region has less effect (21) . Therefore, if the sequence between residues 22 and 30 were a true NES, mutation of the first leucine within the core region, which is residue 28 of BRCA1, would be expected to abrogate this activity. As shown in Fig. 1B , mutation of this leucine to an alanine (L28A) reduced the export activity of the protein by ϳ75%, whereas mutation of the second leucine within the core, located at residue 30, to an alanine (L30A) did not significantly reduce the level of acetylation. When both leucines were mutated, the level of acetylation was reduced to that observed in cells transfected with CMV128 alone. Thus, our data suggest that amino acids 22-30 of BRCA1 act as a leucine-dependent NES.
Comparable Export Activity of BRCA1 Amino Acids 22-30 and 81-99 -To compare the relative abilities of amino acids 22-30 and 81-99 (the previously identified NES) of BRCA1 to act as nuclear export sequences, the Rev complementation assay was performed with oligonucleotides corresponding to amino acids 81-99 fused to the export-defective Rev construct. The export activity was directly compared with that of the 22-30 sequence within BRCA1 (Fig. 2) . In this set of assays, the level of acetylation mediated by amino acid residues 22-30 of BRCA1 was arbitrarily set at 100. The level of acetylation by residues 81-99, which was ϳ80% of that of residues 22-30, was not significantly different from the activity of the 22-30 motif.
Mutation of NES Encoded by Amino Acids 22-30 Leads to Enhanced Nuclear Accumulation of BRCA1-To
substantiate that amino acids 22-30 act as a nuclear export sequence, stable transfectants, expressing wild-type BRCA1 or BRCA1 in which leucine 28 (L28A) or phenylalanine 93 and leucine 95 (m2, mutations within the previously reported NES) were mutated to alanine, were generated in MCF-7 cells. Because the intensity of GFP is reduced in stably transfected cells, indirect immunostaining of GFP was used to detect the protein (Fig. 3) . In cells stably expressing wild-type BRCA1 (pEGFPC1BRCA1), the GFP-tagged protein was predominantly nuclear, although some cytoplasmic staining was detectable. Cells expressing either the m2 (pEGFPC1BRCA1m2) or the L28A (pEGFPC1BRCA1L28A) mutants expressed a completely nuclear GFP-tagged BRCA1. Because Leu-28 is within the RING finger domain of BRCA1, protein localization could potentially be affected by disruption of this motif. To evaluate the effect of disruption of the RING finger on BRCA1 localization, stable transfectants expressing BRCA1 in which cysteine 27 was mutated to glycine (C27G) were also generated. This mutation should disrupt one of the two zinc-binding sites (site 1) within the RING finger of BRCA1 (27) . As seen in Fig. 3 , the C27G mutant protein (pEGFPC1BRCA1C27G) localized similarly to wild-type BRCA1 and was predominantly nuclear with detectable cytoplasmic staining. This finding suggested that mutation within the RING finger motif did not perturb the localization profile of BRCA1 to result in nuclear accumulation of the protein. Thus, the nuclear accumulation of the protein Results shown are the -fold increases in acetylation when compared with that of CMV128 alone, which was arbitrarily set at 1 (n ϭ 3, mean Ϯ S.E.; **, p Ͻ 0.01 by analysis of variance). B, the core leucines in the leucine 22-30 sequence were mutated to alanines, and CAT activity was assessed (n ϭ 3, mean Ϯ S.E.; **, p Ͻ 0.01 by analysis of variance).
FIG. 2.
Comparison of the nuclear export activity of BRCA1 amino acids 22-30 and 81-99. Residues 22-30 and 81-99 within BRCA1 were analyzed for their ability to confer nuclear export to HIV-1 Rev as determined by the measurement of CAT activity. Results shown are the relative levels of acetylation mediated by amino acid residues 81-99 when compared with that mediated by amino acid residues 22-30, which was arbitrarily set at 100% (n ϭ 3, mean Ϯ S.E.).
was likely because of disruption of the nuclear export activity of residues 22-30.
DISCUSSION
Although the tumor suppressor BRCA1 is involved in many functions that would require a nuclear localization of the protein, it undergoes dynamic shuttling between the nucleus and cytoplasm. This movement has been attributed to its active nuclear import, mediated through binding to importin ␣ (12), and nuclear export mediated through the CRM1 pathway (19) . In the initial report describing nuclear export of BRCA1, Rodriguez and Henderson (19) mapped the nuclear localization sequence to amino acids 81-99. The authors (19) also indicated that no export activity was present within the first 70 amino acids of BRCA1. This was based on the observation that when these residues were deleted, the protein displayed cytoplasmic localization. However, a subsequent report (28) demonstrated that the cytoplasmic localization was due to reduced nuclear import and not to sustained nuclear export. Thus, the findings from these two studies do not exclude the possibility of a NES within the first 70 amino acid residues of BRCA1.
In this study, we demonstrate that there is a second motif within BRCA1, amino acids 22-30, that is equally capable of mediating nuclear export as the sequence between amino acids 81 and 99. Our conclusion is based on three observations. First, the 22-30 sequence closely fits the consensus pattern of hydrophobic residues characteristic of Rev-like export sequences and has the third highest NES motif score based on NetNES. Second, this sequence can mediate nuclear export of an exportdefective Rev fusion protein at a level similar to that of the 81-99 sequence. Third, mutation of the critical leucine in the core region of this sequence abrogates export in a Rev fusion protein and results in nuclear sequestration of the pEGFPC1BRCA1 protein. Because mutation of either NES at residues 81-99 or 22-30 resulted in nuclear accumulation of the BRCA1, it appears that both sequences are required for efficient nuclear export of BRCA1. Collectively, these data suggest that BRCA1 harbors at least two functioning NES.
The physiological significance of two NES in BRCA1 is presently unclear. However, it is not uncommon for tumor suppressors to have multiple NES. p53 has two NES located at amino acids 11-27 (16) and 340 -351 (15) . The 11-27 sequence is inactivated upon phosphorylation of serine 15 induced by ultraviolet radiation, whereas the 340 -351 sequence, which lies within the tetramerization domain of p53, appears to be masked when p53 is in its tetrameric state. Thus, inactivation of either one of these sequences leads to the nuclear accumulation and increased activity of p53. Adenomatous polyposis coli also has two leucine-rich NES, and at least one of these sequences, amino acids 165-174, is masked. It is possible that cell density-dependent signaling as well as phosphorylation/ dephosphorylation controls the masking of this sequence (13, 14) . Whether similar events regulate the availability of BRCA1 export sequences is not known. BRCA1 interacts with BARD1 through their respective RING fingers. As a result, BARD1 masks the 81-99 NES of BRCA1 (28) . However, what regulates the interaction between the two proteins, and thus the masking of the NES, is not understood. Although the leucine at residue 28 of BRCA1 does not appear to be directly involved in the BRCA1-BARD1 interaction, accessibility of the 22-30 sequence could still be influenced by the interaction. The effect of interaction of BRCA1 and BARD1 on the function of the NES at amino acid residues 22-30 has yet to be examined. Nevertheless, the present findings provide evidence for a second nuclear export sequence in BRCA1, which provides another level of regulation of the nuclear-cytoplasmic shuttling important in the biology and perhaps the pathophysiology of this tumor suppressor protein.
